Literature DB >> 23416012

Three-dimensional esophagus reconstruction and monitoring during ablation of atrial fibrillation: combination of two imaging techniques.

Fernando A Scazzuso1, Santiago H Rivera, Gastón Albina, María de la Paz Ricapito, Luis Alberto Gómez, Victoria Sanmartino, Matías Kamlofsky, Ruben Laiño, Alberto Giniger.   

Abstract

OBJECTIVE: The purpose of the study was to determine the accuracy of a novel three-dimensional (3D) imaging integration technique of the esophagus combining multislice computed tomography (CT) scan of the esophagus into the three-dimensional (3D) electroanatomic map just before pulmonary vein (PV) isolation.
METHODS: We included 94 consecutive patients with symptomatic atrial fibrillation (AF) who underwent ablation. All patients had a CT performed prior procedure that was integrated to the 3D reconstruction electromechanical map of the atrium and the esophagus (Verismo(TM), EnSite® NavX version 7.0 J, St. Jude Medical Inc.). During the procedure, a quadripolar electrophysiology catheter placed in the esophagus was used for mapping and to monitor esophagus position. Integrated (fusion) images were used to determinate the esophagus position compared to the left atrium posterior wall and its relationship with PV ostiums. We compared esophagus position by CT and fusion images.
RESULTS: Procedural success was 97.9% with no fatal complications. Esophagus locations were as follows: left 57%, right 7%, oblique course 11% and central 25%. Agreements in esophageal position between CT and fusion imaging techniques were 83.3% and 64% for patients with a recent (≤48 h) and non-recent CT assessment (>48 h), respectively. Throughout the procedure, esophagus stability was 88.8% (lateral displacement<15 mm). Ablative strategy was modified in 51% of the cases due to awareness of esophagus location.
CONCLUSION: Guidance of AF ablation with 3D fusion images was safe and effective. CT images of the esophagus, especially if acquired within 48 h before ablation, ensure appropriate intraprocedural localization of the esophagus.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Ablation; Atrial fibrillation; Electroanatomical mapping system; Esophagus

Mesh:

Year:  2013        PMID: 23416012     DOI: 10.1016/j.ijcard.2013.01.026

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Esophageal luminal temperature rise during atrial fibrillation ablation is associated with lower radiofrequency electrode distance and baseline impedance.

Authors:  Mirmilad Khoshknab; Ling Kuo; Tarek Zghaib; Jeffrey Arkles; Pasquale Santangeli; Francis E Marchlinski; Yuchi Han; Benoit Desjardins; Saman Nazarian
Journal:  J Cardiovasc Electrophysiol       Date:  2021-05-28       Impact factor: 2.942

2.  The esophagus going steady.

Authors:  Tina Baykaner; Duy T Nguyen
Journal:  J Cardiovasc Electrophysiol       Date:  2022-03-21       Impact factor: 2.942

3.  Use of oral gadobenate dimeglumine to visualise the oesophagus during magnetic resonance angiography in patients with atrial fibrillation prior to catheter ablation.

Authors:  Riccardo Faletti; Alessandro Rapellino; Francesca Barisone; Matteo Anselmino; Federico Ferraris; Paolo Fonio; Fiorenzo Gaita; Giovanni Gandini
Journal:  J Cardiovasc Magn Reson       Date:  2014-06-13       Impact factor: 5.364

4.  Concentrated pineapple juice for visualisation of the oesophagus during magnetic resonance angiography before atrial fibrillation radiofrequency catheter ablation.

Authors:  Riccardo Faletti; Marco Gatti; Andrea Di Chio; Marco Fronda; Matteo Anselmino; Federico Ferraris; Fiorenzo Gaita; Paolo Fonio
Journal:  Eur Radiol Exp       Date:  2018-11-21

Review 5.  Applications of multimodality imaging for left atrial catheter ablation.

Authors:  Caroline H Roney; Charles Sillett; John Whitaker; Jose Alonso Solis Lemus; Iain Sim; Irum Kotadia; Mark O'Neill; Steven E Williams; Steven A Niederer
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-12-18       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.